US 12,233,081 B2
Hygromycin a compounds and methods of treating spirochete diseases
Kim Lewis, Newton, MA (US); Yu Imai, Boston, MA (US); Xiaoqian (Wendy) Wu, Boston, MA (US); Anthony D'Onofrio, Northborough, MA (US); Nadja Leimer, Schattdorf (CH); and Akira Iinishi, Newton, MA (US)
Assigned to NORTHEASTERN UNIVERSITY, Boston, MA (US)
Appl. No. 17/269,189
Filed by Kim Lewis, Newton, MA (US); Yu Imai, Boston, MA (US); Xiaoqian (Wendy) Wu, Boston, MA (US); Anthony D'Onofrio, Northborough, MA (US); Nadja Leimer, Schattdorf (CH); and Akira Iinishi, Newton, MA (US)
PCT Filed Aug. 19, 2019, PCT No. PCT/US2019/047031
§ 371(c)(1), (2) Date Feb. 17, 2021,
PCT Pub. No. WO2020/041179, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/719,983, filed on Aug. 20, 2018.
Prior Publication US 2021/0275559 A1, Sep. 9, 2021
Int. Cl. A61K 31/7048 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/7048 (2013.01) [A61P 31/04 (2018.01)] 20 Claims
 
1. A method of treating a disease associated with a spirochete in an animal, comprising: administering to the animal in need of treatment thereof a compound according to formula (XVII), a pharmaceutically acceptable salt, a hydrate, or a solvate thereof:

OG Complex Work Unit Chemistry
thereby treating the disease associated with the spirochete,
wherein the disease associated with the spirochete is Lyme disease;
wherein treatment with the compound, the pharmaceutically acceptable salt, the hydrate, or the solvate thereof, does not increase relative abundance of Enterococcaceae in the animal; and
wherein the animal is a human.